Welcome to our dedicated page for Cytomx Therapeutics SEC filings (Ticker: CTMX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking R&D swings at a clinical-stage biotech is hard enough—doing it inside CytomX Therapeutics’ two-hundred-plus-page reports can feel impossible. If you have ever typed “Where can I find the CytomX Therapeutics quarterly earnings report 10-Q filing?” or “How do I monitor CytomX Therapeutics insider trading Form 4 transactions?”, you already know the challenge. Stock Titan turns that complexity into clarity, with CytomX Therapeutics SEC filings explained simply.
Our AI reads every submission the moment it lands on EDGAR, then delivers plain-English takeaways you can trust. Need the CytomX Therapeutics annual report 10-K simplified? Prefer the CytomX Therapeutics 8-K material events explained in one paragraph? Looking for the CytomX Therapeutics proxy statement executive compensation table without scrolling? It’s all here—plus real-time alerts that flag CytomX Therapeutics Form 4 insider transactions right as they post.
Because CytomX relies on milestone payments and collaboration revenue, a single footnote can shift valuation models overnight. Stock Titan’s AI highlights those footnotes, compares cash-burn trends, and links trial updates across quarters so you don’t miss a beat. Use the platform to:
- Compare R&D expense paths quarter-over-quarter through CytomX Therapeutics earnings report filing analysis
- Track leadership equity grants via CytomX Therapeutics executive stock transactions Form 4
- Receive push notifications on CytomX Therapeutics Form 4 insider transactions real-time
- Download clean tables for valuation and diligence models
Understanding CytomX Therapeutics SEC documents with AI means spending minutes—not hours—on the disclosures that drive this pioneering probody technology developer.
Perceptive Advisors, Joseph Edelman and Perceptive Life Sciences Master Fund report a shared beneficial ownership stake of 9,680,185 shares in CytomX Therapeutics, representing 5.9% of the outstanding common stock based on 164,912,906 shares outstanding. The Master Fund directly holds the shares, while Perceptive Advisors, as investment manager, and Mr. Edelman, as managing member, may be deemed to beneficially own those shares. All three reporting persons disclose no sole voting or dispositive power and shared voting and dispositive power over the reported shares.
OrbiMed Advisors LLC reported beneficial ownership of 8,461,500 shares of CytomX Therapeutics common stock, representing 5.4% of the class. The Schedule 13G filing states OrbiMed has shared voting and dispositive power over all reported shares and no sole voting or dispositive power. The filing identifies the reporting person as an investment adviser organized in Delaware and confirms these shares are held on behalf of other persons. The filing includes a certification that the position was not acquired to change or influence control of the issuer.
Point72 entities and Steven A. Cohen reported a 5.1% passive stake in CytomX Therapeutics (CTMX). The filing shows 8,084,623 shares are beneficially owned jointly by Point72 Asset Management, Point72 Capital Advisors and Mr. Cohen, with shared voting and dispositive power and no sole voting or dispositive power reported. The disclosure states these shares are held through Point72 Associates and that the positions were not acquired to influence control of the company. Ownership totals are reported as of the close of business on June 30, 2025.
Tang Capital Management and related entities report ownership of 11,065,662 shares of CytomX Therapeutics common stock, representing 7.0% of the outstanding class. The filing shows no sole voting or dispositive power; all reported shares are held with shared voting and dispositive power. The percentages are calculated using 157,544,369 shares outstanding per the issuer prospectus. The filers certify the stake is not held to influence control of the company.
On August 13, 2025, CytomX Therapeutics provided an update on its CX-2051 Phase 1 study. Dose expansions at 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg, given every three weeks, have each enrolled approximately 20 patients as planned. The company reported a single Grade 5 treatment-related acute kidney injury in a patient with a complex medical history, including a solitary kidney; the event was believed to be secondary to nausea, vomiting and diarrhea and was reported to the FDA on July 18, 2025. The study's Safety Review Committee convened on July 14, 2025 and supported continued study execution and enrollment.
The CTMX-2051-101 study remains ongoing and a Phase 1 data update is expected by Q1 2026. The filing discloses enrollment progress, the serious adverse event and regulatory reporting but does not provide additional efficacy or broader safety data.
CytomX Therapeutics (CTMX) filed a Form S-8 on 7 Aug 2025 to register 4,381,320 additional common shares for issuance under its Amended & Restated 2015 Equity Incentive Plan. The statement incorporates eleven prior S-8 filings and updates only the exhibit section (legal opinion, auditor consent, revised plan documents).
The company is classified as an accelerated filer and a smaller reporting company. Shares will be issued as option grants, RSUs or other awards vest and are exercised; no immediate cash proceeds are expected. Although the filing does not include financial results, the newly registered shares expand the equity pool, enabling continued employee compensation but creating potential dilution for existing shareholders. All required signatures, powers of attorney and fee calculations are provided.
CytomX Therapeutics (CTMX) Q2-25 10-Q snapshot
Six-month collaboration revenue inched up 4% YoY to $69.6 million, buoyed by Astellas milestones and BMS research fees. Tight cost control (R&D –32% to $32.2 million; G&A flat at $16.1 million) flipped YTD operating loss into a $23.4 million net profit (vs. $7.3 million profit LY), largely from $61.8 million of deferred-revenue recognition tied to Amgen and BMS program terminations. Q2 revenue fell 26% YoY to $18.7 million, producing a modest $0.2 million quarterly loss.
Liquidity strengthened: cash, equivalents and Treasuries rose to $159.5 million (Dec-24: $101.9 million) on a $93.4 million May follow-on offering. Share count is 164.9 million (31 Jul 25). Stockholders’ equity swung to $119.9 million from a $(0.5) million deficit.
- Restructuring: 40 % workforce cut; $3.0 million charges booked.
- Pipeline: CX-2051 showed 28 % ORR (43 % at 10 mg/kg) in Phase 1 colorectal cancer; dose expansions ongoing. CX-801 monotherapy escalation at dose-level 4; Keytruda combo started.
- Collaborations: Amgen EGFR TCE and BMS CTLA-4 licenses ended; remaining deferred revenue $32.3 million expected through 2027.
- Balance-sheet risk: $4.2 million uncertain tax liability from California audit.
FAQ
What is the current stock price of Cytomx Therapeutics (CTMX)?
What is the market cap of Cytomx Therapeutics (CTMX)?
